Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 7—July 2018
Research

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada

Salaheddin M. MahmudComments to Author , Songul Bozat-Emre, Luiz C. Mostaço-Guidolin, and Ruth Ann Marrie
Author affiliations: University of Manitoba, Winnipeg, Manitoba, Canada (S.M. Mahmud, S. Bozat-Emre, R.A. Marrie); Government of Manitoba, Winnipeg (L.C. Mostaço-Guidolin); Health Sciences Centre, Winnipeg (R.A. Marrie)

Main Article

Table 2

Crude and age-standardized rates of incident multiple sclerosis and influenza vaccination status, Manitoba, Canada, 2009–2012*

Vaccination status
No. events
Rate (95% CI)
Rate ratio (95% CI)
Crude
Age-standardized
Crude
Age-adjusted
1 year after index date
Unvaccinated 106 23.2 (19.2–28.0) 24.2 (20.1–28.3) 1 1
Vaccinated A(H1N1) pdm09/TIV 69 19.1 (15.1–24.2) 20.2 (15.4–24.9) 0.8 (0.6–1.1) 0.8 (0.3–2.2)
A(H1N1)pdm09 alone 43 17.6 (13.1–23.8) 17.7 (14.1–21.2) 0.8 (0.5–1.1) 0.7 (0.3–1.7)
Concurrent A(H1N1)pdm09/TIV 12 20.3 (11.5–35.7) 19.4 (8.6–30.2) 0.9 (0.5–1.6) 0.8 (0.1–5.0)
TIV alone 14 24.3 (14.4–41.1) 36.8 (25.0–48.6) 1.0 (0.6–1.8) 1.5 (0.3–6.8)
Adjuvanted A(H1N1)pdm09 alone 40 17.1 (12.5–23.3) 17.4 (13.8–21.1) 0.7 (0.5–1.1) 0.7 (0.3–1.7)
Concurrent adjuvanted A(H1N1)pdm09/TIV 11 19.2 (10.6–34.7) 18.3 (7.3–29.3) 0.8 (0.4–1.5) 0.8 (0.1–5.1)
Unadjuvanted A(H1N1)pdm09 alone s s 18.6 (8.8–28.3) 1.3 (0.4–4.2) 0.8 (0.1–4.2)
Concurrent unadjuvanted A(H1N1)pdm09/TIV
s
s
37.9 (13.8–62.0)

2.3 (0.3–16.4)
1.6 (0.1–26.6)
Entire follow-up period
Unvaccinated 188 15.6 (13.5–18.0) 16.0 (13.5–18.5) 1 1
Vaccinated A(H1N1)pdm09/TIV 132 15.1 (12.7–17.9) 15.4 (12.4–18.4) 1.0 (0.8–1.2) 1.0 (0.5–1.9)
A(H1N1)pdm09 alone 82 14.6 (11.7–18.1) 14.9 (9.3–20.5) 0.9 (0.7–1.2) 0.9 (0.3–2.8)
Concurrent A(H1N1)pdm09/TIV 33 20.1 (14.3–28.2) 18.2 (11.8–24.6) 1.3 (0.9–1.9) 1.1 (0.4–3.6)
TIV alone 17 11.4 (7.1–18.4) 16.6 (9.5–23.8) 0.7 (0.4–1.2) 1.0 (0.3–3.9)
Adjuvanted A(H1N1)pdm09 alone 78 14.5 (11.6–18.0) 15.0 (9.3–20.7) 0.9 (0.7–1.2) 0.9 (0.3–2.9)
Concurrent adjuvanted A(H1N1)pdm09/TIV 32 20.1 (14.2–28.4) 18.4 (11.9–24.9) 1.3 (0.9–1.9) 1.1 (0.4–3.7)
Unadjuvanted A(H1N1)pdm09 alone s s 9.7 (3.6–15.8) 1.1 (0.4–2.9) 0.6 (0.1–2.6)
Unadjuvanted A(H1N1)pdm09/TIV s s 13.1 (0.0–27.2) 1.2 (0.2–8.5) 0.8 (0.0–13.5)

*Rates are per 100,000 person-years. A(H1N1)pdm09, pandemic influenza A(H1N1) strain; s, suppressed because of small sample size (n = 1–5) in accordance with the requirements of the data custodian; TIV, trivalent influenza vaccine.

Main Article

Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external